Association of hypertension and diabetes with COVID-19 severity in comparison to healthy patients.

Q3 Medicine
Journal of Circulating Biomarkers Pub Date : 2025-10-07 eCollection Date: 2025-01-01 DOI:10.33393/jcb.2025.3561
Muslima Mahmood Ismail, Abdulhakeem D Hussein, Othman Ghazi Najeeb, Mohammed Hadi Ali Al-Jumaili
{"title":"Association of hypertension and diabetes with COVID-19 severity in comparison to healthy patients.","authors":"Muslima Mahmood Ismail, Abdulhakeem D Hussein, Othman Ghazi Najeeb, Mohammed Hadi Ali Al-Jumaili","doi":"10.33393/jcb.2025.3561","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The coronavirus is a novel pandemic disease that began in Wuhan, China, and further spread globally. Therefore, the aim of this retrospective work was to look at the clinical characteristics and outcomes of diabetic and blood pressure patients compared with a healthy patient who was infected with coronavirus disease (COVID-19).</p><p><strong>Methods: </strong>Data and outcomes were gathered from medical records and analyzed in 150 patients. The disease is frequently diagnosed via nucleic acid-based viral identification from swabs, sputum, or bronchial alveolar lavage fluid (BALF) using diagnostic reagents such as quantitative reverse transcription-polymerase chain reaction (RT-qPCR). COVID-19 chest radiographs were obtained, and clinical characteristics and outcomes were evaluated. In this study, we analyzed and compared the severity of the disease, its outcome, any associated complications, and clinical laboratory findings in COVID-19 patients between diabetic, hypertensive, and healthy individuals.</p><p><strong>Results and conclusion: </strong>According to the findings, COVID-19 can cause a wide range of symptoms, which range from asymptomatic to severe respiratory problems and death. Diabetes appears to be one of the most significant comorbidities associated with a worse COVID-19 result. COVID-19 patients with diabetes (50 (33%) and hypertension (50 (33%)) had more ICU admissions compared with the non-diabetic and non-blood pressure patients (50 (33%)). During the treatment follow-up, 10 (6.6%) of the 150 patients passed away, 140 (93%) were released, 110 (73%) were discharged, and 30 (20%) kept in the hospital. Compared to non-diabetic and healthy COVID-19 patients, diabetic COVID-19 patients had a greater mortality rate.</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"14 ","pages":"39-45"},"PeriodicalIF":0.0000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503036/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Circulating Biomarkers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33393/jcb.2025.3561","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The coronavirus is a novel pandemic disease that began in Wuhan, China, and further spread globally. Therefore, the aim of this retrospective work was to look at the clinical characteristics and outcomes of diabetic and blood pressure patients compared with a healthy patient who was infected with coronavirus disease (COVID-19).

Methods: Data and outcomes were gathered from medical records and analyzed in 150 patients. The disease is frequently diagnosed via nucleic acid-based viral identification from swabs, sputum, or bronchial alveolar lavage fluid (BALF) using diagnostic reagents such as quantitative reverse transcription-polymerase chain reaction (RT-qPCR). COVID-19 chest radiographs were obtained, and clinical characteristics and outcomes were evaluated. In this study, we analyzed and compared the severity of the disease, its outcome, any associated complications, and clinical laboratory findings in COVID-19 patients between diabetic, hypertensive, and healthy individuals.

Results and conclusion: According to the findings, COVID-19 can cause a wide range of symptoms, which range from asymptomatic to severe respiratory problems and death. Diabetes appears to be one of the most significant comorbidities associated with a worse COVID-19 result. COVID-19 patients with diabetes (50 (33%) and hypertension (50 (33%)) had more ICU admissions compared with the non-diabetic and non-blood pressure patients (50 (33%)). During the treatment follow-up, 10 (6.6%) of the 150 patients passed away, 140 (93%) were released, 110 (73%) were discharged, and 30 (20%) kept in the hospital. Compared to non-diabetic and healthy COVID-19 patients, diabetic COVID-19 patients had a greater mortality rate.

与健康患者相比,高血压和糖尿病与COVID-19严重程度的关系
简介:冠状病毒是一种新型大流行疾病,起源于中国武汉,并进一步在全球传播。因此,本回顾性研究的目的是将糖尿病和高血压患者的临床特征和结果与感染冠状病毒病(COVID-19)的健康患者进行比较。方法:对150例患者的病历资料和结果进行分析。该疾病通常通过使用定量逆转录聚合酶链反应(RT-qPCR)等诊断试剂,从拭子、痰液或支气管肺泡灌洗液(BALF)中进行基于核酸的病毒鉴定来诊断。获得COVID-19胸片,评估临床特征和结局。在这项研究中,我们分析并比较了糖尿病、高血压和健康人群中COVID-19患者的疾病严重程度、预后、任何相关并发症和临床实验室结果。结果和结论:根据研究结果,COVID-19可引起广泛的症状,从无症状到严重的呼吸系统问题和死亡。糖尿病似乎是与COVID-19结果恶化相关的最重要的合并症之一。新冠肺炎合并糖尿病(50例(33%))和高血压(50例(33%))患者的ICU入院率高于非糖尿病和非血压患者(50例(33%))。治疗随访期间,150例患者死亡10例(6.6%),出院140例(93%),出院110例(73%),留院30例(20%)。与非糖尿病和健康患者相比,糖尿病患者的死亡率更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Circulating Biomarkers
Journal of Circulating Biomarkers Medicine-Biochemistry (medical)
CiteScore
3.20
自引率
0.00%
发文量
9
审稿时长
8 weeks
期刊介绍: Journal of Circulating Biomarkers is an international, peer-reviewed, open access scientific journal focusing on all aspects of the rapidly growing field of circulating blood-based biomarkers and diagnostics using circulating protein and lipid markers, circulating tumor cells (CTC), circulating cell-free DNA (cfDNA) and extracellular vesicles, including exosomes, microvesicles, microparticles, ectosomes and apoptotic bodies. The journal publishes high-impact articles that deal with all fields related to circulating biomarkers and diagnostics, ranging from basic science to translational and clinical applications. Papers from a wide variety of disciplines are welcome; interdisciplinary studies are especially suitable for this journal. Included within the scope are a broad array of specialties including (but not limited to) cancer, immunology, neurology, metabolic diseases, cardiovascular medicine, regenerative medicine, nosology, physiology, pathology, technological applications in diagnostics, therapeutics, vaccine, drug delivery, regenerative medicine, drug development and clinical trials. The journal also hosts reviews, perspectives and news on specific topics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信